Arvinas Inc
ARVN7.530USD
+0.110+1.48%
收盘 08/04, 16:00（美东）报价延迟15分钟
549.69M总市值
亏损市盈率 TTM
关于 Arvinas Inc 公司
Arvinas, Inc. 是一家临床阶段的生物技术公司。该公司通过其 PROteolysis Targeting Chimera (PROTAC) 蛋白质降解剂平台，率先开发蛋白质降解疗法，旨在利用人体的天然蛋白质处理系统选择性高效地降解和去除致病蛋白质。该公司正在通过临床开发项目推进多种研究药物，包括 vepdegestrant、ARV-393 和 ARV-102。Vepdegestrant 是一种口服生物可利用的 PROTAC 蛋白质降解剂，旨在靶向和降解 ER，用于治疗局部晚期或转移性 ER+/HER2- 乳腺癌患者。该公司正在与辉瑞共同开发 vepdegestrant。ARV-393 是一种口服生物可利用的 PROTAC，旨在降解 BCL6，这是一种转录抑制因子和正常 B 细胞成熟和分化过程的关键调节剂。ARV-102 正在开发中，用于治疗神经退行性疾病。
公司简介
公司代码ARVN
公司名称Arvinas Inc
上市日期Sep 27, 2018
CEODr. John G. Houston, Ph.D.
员工数量430
证券类型Ordinary Share
年结日Sep 27
公司地址5 Science Park
城市NEW HAVEN
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编06511-1966
电话12035351456
网址https://www.arvinas.com/
公司代码ARVN
上市日期Sep 27, 2018
CEODr. John G. Houston, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
Mr. Edward (Ted) Kennedy, Jr.
Mr. Edward (Ted) Kennedy, Jr.
Independent Director
Independent Director
--
--
Dr. Laurie Smaldone Alsup, M.D.
Dr. Laurie Smaldone Alsup, M.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
收入明细
FY2025Q1
FY2024
FY2023
暂无数据
地区USD
名称
营收
占比
United States
188.80M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 7月27日 周日
更新时间: 7月27日 周日
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
11.44%
BlackRock Institutional Trust Company, N.A.
6.90%
Citadel Advisors LLC
5.31%
T. Rowe Price Associates, Inc.
5.14%
Pfizer Inc
4.74%
Other
66.47%
持股股东
持股股东
占比
The Vanguard Group, Inc.
11.44%
BlackRock Institutional Trust Company, N.A.
6.90%
Citadel Advisors LLC
5.31%
T. Rowe Price Associates, Inc.
5.14%
Pfizer Inc
4.74%
Other
66.47%
股东类型
持股股东
占比
Investment Advisor
36.14%
Hedge Fund
24.67%
Investment Advisor/Hedge Fund
17.48%
Venture Capital
6.80%
Corporation
4.74%
Research Firm
3.41%
Individual Investor
2.23%
Sovereign Wealth Fund
1.70%
Pension Fund
0.37%
Other
2.45%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
503
71.52M
97.99%
-18.05M
2025Q1
525
68.48M
93.89%
-22.67M
2024Q4
505
80.31M
116.78%
-4.24M
2024Q3
496
79.95M
116.50%
-140.10K
2024Q2
489
78.26M
114.11%
+1.71M
2024Q1
494
75.44M
110.48%
+3.48M
2023Q4
497
68.16M
100.81%
+12.55M
2023Q3
472
52.04M
94.71%
-3.94M
2023Q2
473
53.77M
100.76%
-3.55M
2023Q1
475
55.60M
104.22%
-4.17M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
8.35M
11.44%
+1.30M
+18.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.04M
6.9%
-246.30K
-4.66%
Mar 31, 2025
Citadel Advisors LLC
3.88M
5.31%
+395.72K
+11.37%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.75M
5.14%
-273.88K
-6.81%
Mar 31, 2025
Pfizer Inc
3.46M
4.74%
--
--
Mar 31, 2025
RTW Investments L.P.
3.33M
4.57%
--
--
Mar 31, 2025
Logos Global Management LP
3.30M
4.52%
+3.30M
--
Jun 10, 2025
Opaleye Management Inc.
1.98M
2.71%
+350.00K
+21.54%
Mar 31, 2025
State Street Global Advisors (US)
1.90M
2.6%
+259.14K
+15.83%
Mar 31, 2025
Alyeska Investment Group, L.P.
1.80M
2.47%
+1.80M
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
SPDR S&P Pharmaceuticals ETF
1.09%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.77%
Invesco NASDAQ Future Gen 200 ETF
0.46%
Tema Oncology ETF
0.41%
Federated Hermes MDT Small Cap Core ETF
0.3%
iShares U.S. Pharmaceuticals ETF
0.25%
Zacks Small/Mid Cap ETF
0.18%
JPMorgan Fundamental Data Science Small Core ETF
0.15%
Tema Neuroscience and Mental Health ETF
0.15%
查看更多
SPDR S&P Pharmaceuticals ETF
占比1.09%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.88%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比0.77%
Invesco NASDAQ Future Gen 200 ETF
占比0.46%
Tema Oncology ETF
占比0.41%
Federated Hermes MDT Small Cap Core ETF
占比0.3%
iShares U.S. Pharmaceuticals ETF
占比0.25%
Zacks Small/Mid Cap ETF
占比0.18%
JPMorgan Fundamental Data Science Small Core ETF
占比0.15%
Tema Neuroscience and Mental Health ETF
占比0.15%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
